Variation in Resistance Traits, Phylogenetic Backgrounds, and Virulence Genotypes among Escherichia coli Clinical Isolates from Adjacent Hospital Campuses Serving Distinct Patient Populations

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5331-5339

  Drawz, Sarah M ^a   Porter, Stephen ^a   Kuskowski, Michael A ^a   Johnston, Brian ^a   Clabots, Connie ^a   Kline, Susan ^a   Ferrieri, Patricia ^a   Johnson, James R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; ESCHERICHIA COLI PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; ENZYME SYNTHESIS; ESCHERICHIA COLI; GENETIC TRAIT; GENOTYPE; NONHUMAN; PEDIATRIC HOSPITAL; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; DRUG EFFECTS; GENETICS; HOSPITAL; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PATHOGENICITY; VIRULENCE;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; GENOTYPE; HOSPITALS; HUMANS; PHYLOGENY; VIRULENCE;

EID: 84940928129     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00048-15     Document Type: Article

References (34)

1. Nicolas-Chanoine MH, Bertrand X, Madec JY. 2014. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 27:543-574. http: //dx.doi.org/10.1128/CMR.00125-13.
2. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 51:286-294. http://dx.doi.org/10.1086/653932.
3. Rogers BA, Sidjabat HE, Paterson DL. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66:1-14. http://dx.doi.org/10.1093/jac/dkq415.
4. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Caniça MM, Park YJ, Lavigne JP, Pitout J, Johnson JR. 2008. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61:273-281.
5. Williamson DA, Freeman JT, Porter S, Roberts S, Wiles S, Paterson DL, Johnson JR. 2013. Clinical and molecular correlates of virulence in Escherichia coli causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. J Antimicrob Chemother 68: 2898-2906. http://dx.doi.org/10.1093/jac/dkt276.
6. Accogli M, Giani T, Monaco M, Giufrè M, García-Fernández A, Conte V, D'Ancona F, Pantosti A, Rossolini GM, Cerquetti M. 2014. Emergence of Escherichia coli ST131 sub-clone H30 producing VIM-1 and KPC-3 carbapenemases, Italy. J Antimicrob Chemother 69:2293-2296. http://dx.doi.org/10.1093/jac/dku132.
7. O'Hara JA, Hu F, Ahn C, Nelson J, Rivera JI, Pasculle AW, Doi Y. 2014. Molecular epidemiology of KPC-producing Escherichia coli: occurrence of ST131-fimH30 subclone harboring pKpQIL-like IncFIIk plasmid. Antimicrob Agents Chemother 58:4234-4237. http://dx.doi.org/10 .1128/AAC.02182-13.
8. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers P, Qin X, Butler-Wu S, Price LB, Aziz M, Nicolas-Chanoine MH, Debroy C, Robicsek A, Hansen G, Urban C, Platell J, Trott DJ, Zhanel G, Weissman SJ, Cookson BT, Fang FC, Limaye AP, Scholes D, Chattopadhyay S, Hooper DC, Sokurenko EV. 2013. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 207:919-928. http://dx.doi.org/10.1093 /infdis/jis933.
9. Banerjee R, Johnston B, Lohse C, Chattopadhyay S, Tchesnokova V, Sokurenko EV, Johnson JR. 2013. The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics. Antimicrob Agents Chemother 57:5912-5917. http://dx.doi.org/10 .1128/AAC.01065-13.
10. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, Andersen PS, Pearson T, Riddell K, Rogers P, Scholes D, Kahl B, Keim P, Sokurenko EV. 2013. The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30Rx. mBio 4:e00377- 00313.
11. Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, Phan MD, Gomes Moriel D, Peters KM, Davies M, Rogers BA, Dougan G, Rodriguez-Baño J, Pascual A, Pitout JD, Upton M, Paterson DL, Walsh TR, Schembri MA, Beatson SA. 2014. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci USA111:5694-5699. http://dx.doi.org/10.1073/pnas .1322678111.
12. Banerjee R, Johnson JR. 2014. A new clone sweeps clean: the enigmatic experience of Escherichia coli sequence type 131. Antimicrob Agents Chemother 58:4997-5004. http://dx.doi.org/10.1128/AAC.02824-14.
13. Olesen B, Frimodt-Møller J, Leihof RF, Struve C, Johnston B, Hansen DS, Scheutz F, Krogfelt KA, Kuskowski MA, Clabots C, Johnson JR. 2014. Temporal trends in antimicrobial resistance and virulenceassociated traits within the Escherichia coli sequence type 131 clonal group and its H30 and H30Rx subclones, 1968 to 2012. Antimicrob Agents Chemother 58:6886-6895. http://dx.doi.org/10.1128/AAC.03679-14.
14. Banerjee R, Robicsek A, Kuskowski MA, Porter S, Johnston BD, Sokurenko E, Tchesnokova V, Price LB, Johnson JR. 2013. Molecular epidemiology of Escherichia coli sequence type 131 and Its H30 and H30Rx subclones among extended-spectrum-beta-lactamase-positive and -nega-tive E. coli clinical isolates from the Chicago Region, 2007 to 2010. Antimicrob Agents Chemother 57:6385-6388. http://dx.doi.org/10.1128 /AAC.01604-13.
15. Peirano G, Pitout JD. 2014. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a Canadian region with a centralized laboratory system: rapid emergence of the H30Rx sublineage. Antimicrob Agents Chemother 58:2699-2703. http: //dx.doi.org/10.1128/AAC.00119-14.
16. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR, VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. 2013. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among U.S. veterans. Clin Infect Dis 57:1256-1265. http://dx.doi.org/10.1093/cid/cit503.
17. Olesen B, Hansen DS, Nilsson F, Frimodt-Møller J, Leihof RF, Struve C, Scheutz F, Johnston B, Krogfelt KA, Johnson JR. 2013. Prevalence and characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-producing E. coli isolates in Copenhagen, Denmark. J Clin Microbiol 51:1779-1785. http: //dx.doi.org/10.1128/JCM.00346-13.
18. Clermont O, Bonacorsi S, Bingen E. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 66:4555-4558. http://dx.doi.org/10.1128/AEM.66.10.4555-4558.2000.
19. Clermont O, Christenson JK, Denamur E, Gordon DM. 2013. The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. Environ Microbiol Rep 5:58- 65. http://dx.doi.org/10.1111/1758-2229.12019.
20. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. 2009. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 53:2733-2739. http://dx.doi.org/10.1128/AAC .00297-09.
21. Bidet P, Metais A, Mahjoub-Messai F, Durand L, Dehem M, Aujard Y, Bingen E, Nassif X, Bonacorsi S. 2007. Detection and identification by PCR of a highly virulent phylogenetic subgroup among extraintestinal pathogenic Escherichia coli B2 strains. Appl Environ Microbiol 73:2373-2377. http://dx.doi.org/10.1128/AEM.02341-06.
22. Clermont O, Christenson JK, Daubié AS, Gordon DM, Denamur E. 2014. Development of an allele-specific PCR for Escherichia coli B2 subtyping, a rapid and easy to perform substitute of multilocus sequence typing. J Microbiol Methods 101:24-27. http://dx.doi.org/10.1016/j .mimet.2014.03.008.
23. Matsumura Y, Yamamoto M, Nagao M, Hotta G, Matsushima A, Ito Y, Takakura S, Ichiyama S, Kyoto-Shiga Clinical Microbiology Study Group. 2012. Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-β-lactamaseproducing Escherichia coli in Japan. J Antimicrob Chemother 67:2612-2620. http://dx.doi.org/10.1093/jac/dks278.
24. Weissman SJ, Johnson JR, Tchesnokova V, Billig M, Dykhuizen D, Riddell K, Rogers P, Qin X, Butler-Wu S, Cookson BT, Fang FC, Scholes D, Chattopadhyay S, Sokurenko E. 2012. High-resolution two-locus clonal typing of extraintestinal pathogenic Escherichia coli. Appl Environ Microbiol 78:1353-1360. http://dx.doi.org/10.1128/AEM .06663-11.
25. Johnson JR, Murray AC, Gajewski A, Sullivan M, Snippes P, Kuskowski MA, Smith KE. 2003. Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products. Antimicrob Agents Chemother 47:2161-2168. http: //dx.doi.org/10.1128/AAC.47.7.2161-2168.2003.
26. CTX-M-15 among extendedspectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 56:2364-2370. http://dx.doi.org/10 .1128/AAC.05824-11.
27. Leflon-Guibout V, Jurand C, Bonacorsi S, Espinasse F, Guelfi MC, Duportail F, Heym B, Bingen E, Nicolas-Chanoine MH. 2004. Emergence and spread of three clonally related virulent isolates of CTX-M-15-producing Escherichia coli with variable resistance to aminoglycosides and tetracycline in a French geriatric hospital. Antimicrob Agents Chemother 48:3736-3742. http://dx.doi.org/10.1128/AAC.48.10.3736-3742.2004.
28. Johnson JR, Nicolas-Chanoine MH, DebRoy C, Castanheira M, Robicsek A, Hansen G, Weissman S, Urban C, Platell J, Trott D, Zhanel G, Clabots C, Johnston BD, Kuskowski MA, Investigators M. 2012. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerg Infect Dis 18:598- 607. http://dx.doi.org/10.3201 /eid1804.111627.
29. Ribot EM, Fair MA, Gautom R, Cameron DN, Hunter SB, Swaminathan B, Barrett TJ. 2006. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog Dis 3:59-67. http://dx.doi .org/10.1089/fpd.2006.3.59.
30. Johnson JR, Clermont O, Johnston B, Clabots C, Tchesnokova V, Sokurenko E, Junka AF, Maczynska B, Denamur E. 2014. Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131. J Clin Microbiol 52:1358-1365. http://dx.doi.org/10.1128/JCM.03502-13.
31. Johnson JR, Kuskowski MA, Gajewski A, Sahm DF, Karlowsky JA. 2004. Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001. J Infect Dis 190: 1739-1744. http://dx.doi.org/10.1086/425018.
32. Burgess MJ, Johnson JR, Porter SB, Johnston B, Clabots C, Lahr BD, Uhl JR, Banerjee R. 2015. Long-term care facilities are reservoirs for antimicrobial-resistant sequence type 131 Escherichia coli. Open Forum Infect Dis 2:ofv011. http://dx.doi.org/10.1093/ofid/ofv011.
33. Drekonja DM, Johnston B, Porter SB, Clabots C, Amway R, Kuskowski MA, Johnson JR. 2014. Epidemiology of Escherichia coli sequence type 131 in a Veterans Affairs medical center, abstr 342, IDWeek, 8 to 12 October 2014, Philadelphia, PA,
34. Johnson JR, Porter SB, Zhanel G, Kuskowski MA, Denamur E. 2012. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 80:1554-1562. http://dx.doi.org/10 .1128/IAI.06388-11.